Area of research
Oncology · Cancer Research
Research interest
Research interests include HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, and Advanced Breast Cancer Therapies.
Risk Stratification Using Tree-Based Models for Recurrence-Free Survival in Breast Cancer
Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.
Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study
Next-Generation HER2-Targeted ADCs for Treatment of Breast Cancer: Precision Oncology’s New Frontier
HER2-low metastatic breast cancer: molecular insights and therapeutic strategies
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Whole-genome screen identifies diverse pathways that negatively regulate ciliogenesis.
Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Whole-genome screen identifies diverse pathways that negatively regulate ciliogenesis
LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer.
Validation of plasma metabolites associated with breast cancer risk among Mexican Americans.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Immunotherapy and targeted therapy combinations in metastatic breast cancer.
Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer.
Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
Are Biosimilars the Future of Oncology and Haematology?
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Clinical development of CT-P6 in HER2 positive breast cancer.
Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process